Reuters logo
5 years ago
BRIEF-GSK starts Phase III study to evaluate dabrafenib-trametinib combination for melanoma
February 1, 2013 / 12:10 PM / 5 years ago

BRIEF-GSK starts Phase III study to evaluate dabrafenib-trametinib combination for melanoma

LONDON, Feb 1 (Reuters) - GlaxoSmithKline Plc : * Press release: GlaxoSmithKline starts phase iiistudy to test combined

braf/mek inhibition in patients with braf positivemelanoma following surgery * Primary endpoint of the study is relapse-free survival

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below